{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:28:36Z","timestamp":1759411716586},"reference-count":19,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.047","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T18:11:03Z","timestamp":1527963063000},"page":"3717-3720","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reintroducing OPV in Israel on the journey to global polio eradication \u2013 Estimation at a low rate of contraindicated population"],"prefix":"10.1016","volume":"36","author":[{"given":"Chen","family":"Rosenberg Danziger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Anis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethel-Sherry","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itamar","family":"Grotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda L.","family":"Danon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.047_b0005","series-title":"The epidemiology of polio in Israel an historical perspective","author":"Swartz","year":"2008"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.05.047_b0010","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.cmi.2016.06.018","article-title":"Public health response to the silent reintroduction of wild poliovirus to Israel, 2013\u20132014","volume":"22","author":"Moran-Gilad","year":"2016","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.vaccine.2018.05.047_b0015","unstructured":"Israeli Ministry of Health. Israeli vaccination briefing, available online: https:\/\/Www.health.gov.il\/UnitsOffice\/HD\/PH\/epidemiology\/td\/docs\/tadrich_Chisunim.pdf; 2017."},{"key":"10.1016\/j.vaccine.2018.05.047_b0020","doi-asserted-by":"crossref","unstructured":"Yaari R, Kaliner E, Grotto I, et al. Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel. BMC Med. 2016;14(1):95-016-0637-z.","DOI":"10.1186\/s12916-016-0666-7"},{"key":"10.1016\/j.vaccine.2018.05.047_b0025","doi-asserted-by":"crossref","unstructured":"Alawieh A, Sabra Z, Langley EF, Bizri AR, Hamadeh R, Zaraket FA. Assessing the impact of the lebanese national polio immunization campaign using a population-based computational model. BMC Public Health 2017;17(1):902-017-4909-0.","DOI":"10.1186\/s12889-017-4909-0"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.047_b0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.autrev.2011.05.015","article-title":"Immunization in the adult immunocompromised host","volume":"11","author":"Lobermann","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"10088","key":"10.1016\/j.vaccine.2018.05.047_b0035","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(17)30636-0","article-title":"Health and health care in Israel: an introduction","volume":"389","author":"Clarfield","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.047_b0040","first-page":"52","article-title":"\u201cCode blue\u201d for coding discharge diagnoses in the emergency department","volume":"16","author":"Ash","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.vaccine.2018.05.047_b0050","unstructured":"Cohen R, Rabin H. Membership in HMOs 20131. Available online: http:\/\/Www.btl.gov.il\/publications\/survey\/documents\/seker_262.pdf. National insurance institute of Israel; 2014."},{"key":"10.1016\/j.vaccine.2018.05.047_b0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.puhe.2016.10.013","article-title":"Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK","volume":"142","author":"Varghese","year":"2017","journal-title":"Public Health"},{"issue":"47","key":"10.1016\/j.vaccine.2018.05.047_b0060","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1016\/j.vaccine.2012.08.072","article-title":"Estimated size of the population at risk of severe adverse events after smallpox vaccination in Israel","volume":"30","author":"Levy","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.05.047_b0065","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMp1406250","article-title":"Lessons from a public health emergency\u2013importation of wild poliovirus to Israel","volume":"371","author":"Kopel","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.047_b0070","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.047_b0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/apt.14257","article-title":"Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications","volume":"46","author":"Khan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.047_b0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","article-title":"Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept","volume":"48","author":"Borte","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.047_b0085","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.047_b0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1756-185X.2010.01466.x","article-title":"Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis","volume":"13","author":"Badsha","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.047_b0095","first-page":"166","article-title":"Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings","volume":"87","author":"Diaz","year":"1991","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.047_b0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1440-1754.1999.00382.x","article-title":"Varicella vaccine in non-immune household contacts of children with cancer or leukaemia","volume":"35","author":"Kappagoda","year":"1999","journal-title":"J Paediatr Child Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T06:25:11Z","timestamp":1561530311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":19,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306674"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reintroducing OPV in Israel on the journey to global polio eradication \u2013 Estimation at a low rate of contraindicated population","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}